• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List

    1/18/23 8:00:00 AM ET
    $PEAR
    Computer Software: Prepackaged Software
    Technology
    Get the next $PEAR alert in real time by email
    • Pear's prescription digital therapeutics (PDTs), reSET® and reSET-O®, are included on the January 2023 Florida Medicaid Preferred Drug List (PDL), effective January 1, 2023
    • Florida Medicaid is covering reSET® and reSET-O® for the treatment of substance use disorder and opioid use disorder, respectively, giving Medicaid patients in Florida access to innovative FDA-authorized addiction treatments via their mobile devices

    Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the inclusion of its PDTs reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List (PDL). reSET and reSET-O, the only FDA-authorized PDTs for the treatment of substance use disorder and opioid use disorder, respectively, have been added to the Florida Medicaid PDL, effective January 1, 2023.

    In Florida, in August of 2022, there had already been nearly 2,000 overdose deaths for the year.1 In the United States as a whole, the CDC reported more than 107,000 overdose deaths in the 12-month period ending August 2022.2

    "Pear applauds Florida leadership for bringing reSET and reSET-O to its millions of Medicaid members in its persistent efforts to tackle the addiction crisis and bring innovative treatment options to those seeking recovery," said Julia Strandberg, Chief Commercial Officer of Pear Therapeutics. "The unmet need in addiction across the U.S. is enormous, and Florida represents an important step in how we are helping more and more patients by working with states to provide covered access to our products."

    Florida Medicaid has approximately five million Florida residents enrolled, making it the third largest state by enrollment.

    Both reSET and reSET-O have been measured in real-world use and their therapeutic content studied in randomized controlled trials, with results published in peer-reviewed medical journals.3,4 Pear recently released publications showing the potential for improved real-world health outcomes and decreased treatment costs for patients using reSET and reSET-O.5-16 Clinicians receive access to clinical dashboards to inform visits with patients. reSET is used as a monotherapy for patients 18 years of age or older with substance use disorder related to alcohol, cannabis, cocaine, and methamphetamine, and reSET-O is used in combination with buprenorphine-based medication- assisted treatment for patients 18 years of age or older with opioid use disorder.

    reSET Important Safety Information

    Indications for Use:

    reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older, who are currently enrolled in outpatient treatment under the supervision of a clinician. reSET is indicated as a 12-week (90 day) prescription-only treatment for patients with substance use disorder (SUD), who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or who do not abuse opioids as their primary substance of abuse.

    It is intended to:

    • Increase abstinence from a patient's substances of abuse during treatment, and
    • Increase retention in the outpatient treatment program.

    Important Safety Information:

    Warnings: reSET is intended for patients whose primary language is English or Spanish with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

    Clinicians should not use reSET to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

    reSET is not intended to be used as a stand-alone therapy for substance use disorder (SUD). reSET does not replace care by a licensed medical practitioner and is not intended to reduce the amount of face-to-face clinician time. reSET does not represent a substitution for a patient's medication. Patients should continue to take their medications as directed by their healthcare provider.

    Patients with substance use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with substance use disorder also have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should engage in their normal care practices to monitor patients for medical problems and mental health disorders, including risk for harming others and/or themselves.

    The long-term benefit of treatment with reSET on abstinence has not been evaluated in studies lasting beyond 12 weeks (90 days) in the SUD population. The ability of reSET to prevent potential relapse after treatment discontinuation has not been studied.

    The effectiveness of reSET has not been demonstrated in patients currently reporting opioids as their primary substance of abuse.

    This Press Release does not include all the information needed to use reSET safely and effectively. Please see the Clinician Brief Summary for reSET for more information.

    reSET-O Important Safety Information

    Indications for Use:

    reSET-O prescription digital therapeutic is a 12-week (84 day) software application intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic.

    Important Safety Information:

    Warnings/precautions: reSET-O is intended for patients whose primary language is English or Spanish with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET-O is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

    Clinicians should not use reSET-O to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET-O to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

    reSET-O is not intended to be used as a stand-alone therapy for Opioid Use Disorder (OUD). reSET-O does not replace care by a licensed medical practitioner and is not intended to reduce the frequency or duration of in-person therapy. reSET-O does not represent a substitution for a patient's medication. Patients should continue to take their medications as directed by their healthcare provider.

    Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with opioid use disorder have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should undertake standard of care to monitor patients for medical problems and mental health disease, including risk for harming others and/or themselves.

    The long-term benefit of reSET-O has not been evaluated in studies lasting beyond 12 weeks (84 days) in the OUD population. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied.

    This Press Release does not include all the information needed to use reSET-O safely and effectively. Please see the Clinician Brief Summary Instructions for reSET-O for more information.

    About Pear Therapeutics

    Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear's product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear's second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA's traditional 510(k) pathway while simultaneously reviewed through FDA's Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

    References:

    1. https://www.myflfamilies.com/newsroom/pressreleases/2022/20220804-In%20Case%20You%20Missed%20It-Governor%20Ron%20DeSantis%20Announces%20New%20Opioid%20Recovery%20Program%20in%20Florida.shtml
    2. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
    3. Campbell ANC, Nunes EV, Matthews AG, et al. Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry. 2014;171(6):683-690.
    4. Christensen DR, Landes RD, Jackson L, et al. Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014;82(6):964-972. doi:10.1037/a0037496.\
    5. Yuri A. Maricich, MD, Xiaorui Xiong, PhD, Robert Gerwien, PhD, Alice Kuo, BA Fulton Velez, MD MBA, Bruce Imbert, MD PhD, Keely Boyer, MBA, Hilary F. Luderer, PhD, Stephen Braun, BA, Karren Williams, PhD (2020): Real-World evidence for a prescription digital therapeutic to treat Opioid Use Disorder, Journal of Current Medical Research and Opinion, DOI:10.1080/03007995.2020.1846023.
    6. Fulton F. Velez , Sam Colman , Laura Kauffman , Charles Ruetsch & Kathryn Anastassopoulos (2020): Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2021.1840357
    7. Weijia Wang, Nicole Gellings Lowe, Ali Jalali & Sean M. Murphy(2021) Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder, Journal of Medical Economics, 24:1, 61-68, DOI: 1080/13696998.2020.1858581
    8. Yuri A. Maricich, Warren K. Bickel, Lisa A. Marsch, Kirstin Gatchalian, Jeffrey Botbyl & Hilary F. Luderer(2020) Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder, Current Medical Research and Opinion, DOI: 1080/03007995.2020.1846022
    9. Fulton F. Velez, Hilary F. Luderer, Robert Gerwien, Benjamin Parcher, Dylan Mezzio & Daniel C. Malone (2021) Evaluation of the cost-utility of a prescription digital therapeutic for the treatment of opioid use disorder, Postgraduate Medicine, DOI: 1080/00325481.2021.1884471
    10. Fulton F. Velez, Charles Ruetsch & Yuri Maricich (2021) Evidence of long-term real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 1080/14737167.2021.193968
    11. Fulton F. Velez & Daniel C. Malone (2021) Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder, Journal of Market Access & Health Policy, 9:1, DOI: 1080/20016689.2021.1966187
    12. Yuri A. Maricich, Robert Gerwien, Alice Kuo, Daniel C. Malone & Fulton F. Velez(2021) Real-world use and clinical outcomes after 24 weeks of treatment with a prescription digital therapeutic for opioid use disorder, Hospital Practice, DOI: 1080/21548331.2021.1974243
    13. Velez FF, Colman S, Kauffman L, Ruetsch C, Anastassopoulos K, Maricich YA. Comparison of Healthcare Resource Utilization Between Patients Who Engaged or Did Not Engage With a Prescription Digital Therapeutic for Opioid Use Disorder. Clinicoecon Outcomes Res. 2021;13:909-916

      https://doi.org/10.2147/CEOR.S334274
    14. Velez, F.F., Anastassopoulos, K.P., Colman, S. et al. Reduced Healthcare Resource Utilization in Patients with Opioid Use Disorder in the 12 Months After Initiation of a Prescription Digital Therapeutic. Adv Ther (2022). https://doi.org/10.1007/s12325-022-02217-y
    15. Shah, N., Velez, F.F., Colman, S. et al. Real-World Reductions in Healthcare Resource Utilization over 6 Months in Patients with Substance Use Disorders Treated with a Prescription Digital Therapeutic. Adv Ther (2022). https://doi.org/10.1007/s12325-022-02215-0
    16. Luderer H, Campbell A, Nunes E, Enman N, Xiong X, Gerwein R, Maricich Y. Engagement patterns with a digital therapeutic for substance use disorders: Correlations with abstinence outcomes. Journal of Substance Use Disorders. 132 (2021) 108585. https://doi.org/10.1016/j.jsat.2021.108585

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005318/en/

    Get the next $PEAR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PEAR

    DatePrice TargetRatingAnalyst
    1/26/2022$5.00Neutral
    B of A Securities
    1/20/2022$11.00Outperform
    Credit Suisse
    1/3/2022$12.00Buy
    BTIG Research
    12/29/2021$13.00Buy
    Citigroup
    12/22/2021$16.00Buy
    Chardan Capital
    12/16/2021Outperform
    Cowen & Co.
    More analyst ratings

    $PEAR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process

      Pear Therapeutics, Inc. (NASDAQ:PEAR) ("the Company"), a company focused on developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the Company and its wholly owned subsidiary, Pear Therapeutics (US), Inc. (collectively, the "Debtors") each voluntarily filed for protection under chapter 11 ("Chapter 11") of the U.S. Bankruptcy Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") and they intend to pursue a sale of the business or assets under section 363 of the Bankruptcy Code. Prior to the filing of the Chapter 11 cases, the Debtors evaluated a wide ra

      4/7/23 11:30:00 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

      MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

      4/3/23 4:05:00 PM ET
      $GLS
      $PEAR
      $SGHT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Computer Software: Prepackaged Software
      Technology
    • 5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science

      SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade. REZZAYO was developed by Cidara Therapeutics, Inc. (NASDAQ:CDTX), a company seeded and then supported by 5AM Ventures through its Series A and Series B rounds. 5AM's Scott Rocklage served as chair of the board of directors from the company's inception in 2012 through 2019. "Su

      3/23/23 10:19:01 AM ET
      $CDTX
      $ELVN
      $IMPL
      $PEAR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Computer Software: Prepackaged Software

    $PEAR
    Leadership Updates

    Live Leadership Updates

    See more
    • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

      MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

      4/3/23 4:05:00 PM ET
      $GLS
      $PEAR
      $SGHT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Computer Software: Prepackaged Software
      Technology
    • Jorge Gomez Joins Moderna as Chief Financial Officer

      CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel."I am pleased to welcome Jorge to Moderna as our Chief Financial Officer and as a member of the Executive Committee," said Mr. Bancel. "As we grow and scale the company globally, Jorge's experience leading the financial functions of multinational healthcare companies will be an asset to our team. Jorge's passion for sustainabilit

      4/11/22 9:00:00 AM ET
      $CAH
      $MRNA
      $PEAR
      $XRAY
      Other Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Computer Software: Prepackaged Software

    $PEAR
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Pear Therapeutics Inc.

      25-NSE - Pear Therapeutics, Inc. (0001835567) (Subject)

      5/2/23 1:36:49 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Pear Therapeutics, Inc. (0001835567) (Filer)

      4/10/23 4:36:29 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Pear Therapeutics, Inc. (0001835567) (Filer)

      4/7/23 11:32:19 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    $PEAR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B of A Securities initiated coverage on Pear Therapeutics with a new price target

      B of A Securities initiated coverage of Pear Therapeutics with a rating of Neutral and set a new price target of $5.00

      1/26/22 7:01:40 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Credit Suisse initiated coverage on Pear Therapeutics with a new price target

      Credit Suisse initiated coverage of Pear Therapeutics with a rating of Outperform and set a new price target of $11.00

      1/20/22 7:36:22 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • BTIG Research initiated coverage on Pear Therapeutics with a new price target

      BTIG Research initiated coverage of Pear Therapeutics with a rating of Buy and set a new price target of $12.00

      1/3/22 7:33:46 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    $PEAR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by 5am Partners Iv, Llc

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      4/12/23 4:51:37 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Snow Ellen

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      2/17/23 4:14:54 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Brenner Erin K.

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      2/17/23 4:14:18 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    $PEAR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Pear Therapeutics Inc. (Amendment)

      SC 13D/A - Pear Therapeutics, Inc. (0001835567) (Subject)

      4/28/23 4:07:09 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Pear Therapeutics Inc. (Amendment)

      SC 13D/A - Pear Therapeutics, Inc. (0001835567) (Subject)

      4/12/23 4:33:35 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G/A filed by Pear Therapeutics Inc. (Amendment)

      SC 13G/A - Pear Therapeutics, Inc. (0001835567) (Subject)

      2/14/23 4:06:28 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    $PEAR
    Financials

    Live finance-specific insights

    See more
    • Pear Therapeutics Reports Third Quarter 2022 Results

      Grew revenue 24% quarter-over-quarter to $4.1 million Expanded patient access with new state and commercial payors Expanded real-world evidence with new peer reviewed publication Reduced quarter-over-quarter operating expenses and cut expected 2023 operating expenses Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its third quarter ended September 30, 2022. "Pear is making strong and steady progress toward our mission of making PDTs mainstream medicine," said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. "

      11/14/22 4:02:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics to Issue Third Quarter 2022 Financial Results on Monday, November 14, 2022

      Pear Therapeutics, Inc. (the "Company") (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its third quarter 2022 financial results after the close of market on Monday, November 14, 2022. Management will hold its investor conference call and webcast at 4:30 p.m. ET on the same day to discuss the Company's financial and business highlights. To access the live conference call or webcast, participants should register online at https://investors.peartherapeutics.com/news-events/events-presentations. To avoid delays, we encourage participants to register fifteen minutes ahead of the

      10/31/22 4:02:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Reports Second Quarter 2022 Results

      20% quarter-over-quarter revenue growth to $3.3 million Recent real-world health economic data for all three of Pear's commercial products show cost-savings1-3 Recent commercial formulary additions for reSET® and reSET-O® Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its second quarter ended June 30, 2022. "Pear continues to make significant progress in introducing PDTs as an innovative class of medicine," said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. "We believe our evidence generation strategy is de

      8/11/22 4:02:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology